What is Latch Bio?
Headquartered in San Francisco, Latch Bio operates at the intersection of cloud computing and life sciences. The company provides a comprehensive, no-code platform designed to democratize access to bioinformatics pipelines. By offering a centralized environment for data management and visualization, Latch Bio enables researchers to bypass the technical barriers typically associated with large-scale genomic and proteomic analysis. Its market position is defined by its ability to bridge the gap between raw biological data and actionable scientific insights, effectively serving as the operating system for modern biocomputing.
How much funding has Latch Bio raised?
Latch Bio has raised a total of $33M across 2 funding rounds:
Angel/Seed
$5M
Series A
$28M
Angel/Seed (2021): $5M with participation from General Catalyst, Haystack, and Lux Capital
Series A (2022): $28M led by Haystack, Fifty Years, Caffeinated Capital, Hummingbird Ventures, Lux Capital, and Coatue
Key Investors in Latch Bio
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, focusing on frontier areas such as biotechnology and AI.
Caffeinated Capital
Caffeinated Capital is a thesis-agnostic firm that partners with founders from the inception stage, maintaining a diverse portfolio across life sciences, enterprise software, and defense.
General Catalyst
General Catalyst is a venture capital firm focused on supporting transformational business opportunities across multiple sectors, including healthcare and enterprise software, through deep operational expertise.
What's next for Latch Bio?
Looking ahead, Latch Bio is poised to leverage its recent capital injection to deepen its enterprise integration capabilities and expand its library of pre-built bioinformatics tools. As the biocomputing sector matures, the company is well-positioned to capture additional market share by addressing the growing demand for scalable, secure, and user-friendly data infrastructure. Strategic priorities likely include enhancing its cloud-based visualization engine and fostering deeper partnerships with academic and commercial research institutions to accelerate the pace of discovery in the biotechnology space.
See full Latch Bio company page
